Main epidemiological data on cases of malignant neoplasms of the bladder in Saint Petersburg in 2012–2021

Cover Page

Cite item

Full Text

Abstract

Background. Bladder cancer is the most common malignancy of the urinary tract and one of the most common neoplasias in this group. The incidence and mortality rates of the population from bladder cancer differ significantly in different geographical regions of Russia.
Aim. To assess the main epidemiological indicators of malignant neoplasms of the bladder in residents of Saint Petersburg and the regions of Russia.
Materials and methods. The main epidemiological indicators of malignant bladder neoplasms in Saint Petersburg, Russia and individual federal districts for the period 2012–2021 were studied: crude and standardized rates of morbidity, mortality, prevalence, age structure of patients, the number of cases of diagnosis of the disease at various stages, indicators of one-year mortality and 5-year survival, data on completed cases of treatment of bladder neoplasms. Sources of information: Form No. 7 “Information on cases of malignant diseases” and the database of the Medical Information and Analytical Center (Saint Petersburg).
Results. During the period 2012–2021 in Russia, there was an increase in the incidence and prevalence of malignant neoplasms of the bladder. At the same time, mortality rates decreased, and 5-year survival rates increased. This fact indicates the effectiveness of the treatment of patients in this category. In more than 50 % of cases, the disease was detected at stage I of the pathological process, which is due to the proper level of diagnosis. The main medical and statistical indicators in patients with malignant bladder neoplasms in Saint Petersburg are comparable to the average Russian data, and in a number of parameters they exceed them.
Conclusion. Oncourological assistance to the population with malignant neoplasms of the bladder in Saint Petersburg is provided properly. The study of medical and statistical indicators in dynamics can be used to improve the algorithms of medical and diagnostic care for cancer patients.

About the authors

S. V. Popov

St. Luka’s Clinical Hospital

Email: doc.popov@gmail.com
ORCID iD: 0000-0003-2767-7153
SPIN-code: 3830-9539

 46 Chugunnaya St., Saint Petersburg 194044, Russia 

Russian Federation

R. G. Guseynov

St. Luka’s Clinical Hospital;
Saint Petersburg State University

Email: rusfa@yandex.ru
ORCID iD: 0000-0001-9935-0243
SPIN-code: 4222-4601

46 Chugunnaya St., Saint Petersburg 194044, Russia 

7–9 Universitetskaya Naberezhnaya, Saint Petersburg 199034, Russia 

Russian Federation

V. V. Khizha

St. Luka’s Clinical Hospital;
Medical Information-Analytical Center, Ministry of Health of Russia

Email: apink1@yandex.ru
ORCID iD: 0000-0002-4218-0228

 46 Chugunnaya St., Saint Petersburg 194044, Russia 

30 Shkapina St., Saint Petersburg 198095, Russia

Russian Federation

A. V. Yazenok

St. Luka’s Clinical Hospital;
Medical Information-Analytical Center, Ministry of Health of Russia

Email: AYazenok@spbmiac.ru
ORCID iD: 0000-0002-1334-8191

 46 Chugunnaya St., Saint Petersburg 194044, Russia 

 30 Shkapina St., Saint Petersburg 198095, Russia 

Russian Federation

K. V. Sivak

St. Luka’s Clinical Hospital

Email: kvsivak@gmail.com
ORCID iD: 0000-0003-4064-5033
SPIN-code: 7426-8322

 46 Chugunnaya St., Saint Petersburg 194044, Russia 

E. V. Pomeshkin

St. Luka’s Clinical Hospital

Email: lucaclinic@zdrav.spb.ru
SPIN-code: 5661-1947

 46 Chugunnaya St., Saint Petersburg 194044, Russia 

Russian Federation

V. V. Perepelitsa

St. Luka’s Clinical Hospital

Email: perepelitsa_vit@mail.ru
ORCID iD: 0000-0002-7656-4473
SPIN-code: 7445-1996

 46 Chugunnaya St., Saint Petersburg 194044, Russia 

Russian Federation

N. S. Bunenkov

St. Luka’s Clinical Hospital;
I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia;
V.A. Almazov National Medical Research Centre, Ministry of Health of Russia

Author for correspondence.
Email: bunenkov2006@yandex.ru
ORCID iD: 0000-0003-4331-028X
SPIN-code: 3611-1290

 Nikolay Sergeevich Bunenkov 

46 Chugunnaya St., Saint Petersburg 194044, Russia 

6–8 L’va Tolstogo St., Saint Petersburg 197022, Russia

2 Akkuratova St., Saint Petersburg 197341, Russia 

Russian Federation

T. A. Lelyavina

St. Luka’s Clinical Hospital

Email: lucaclinic@zdrav.spb.ru
ORCID iD: 0000-0001-6796-4064
SPIN-code: 5663-1936

46 Chugunnaya St., Saint Petersburg 194044, Russia

Russian Federation

References

  1. Witjes J.A., Babjuk M., Bellmunt J. et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multistakeholder effort (dagger): under the auspices of the EAU-ESMO Guidelines Committees. Eur Urol 2020;77(2):223–50. doi: 10.1016/j.eururo.2019.09.035
  2. Teoh J.Y., Huang J., Ko W.Y. et al. Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita. Eur Urol 2020;78(6):893–906. doi: 10.1016/j.eururo.2020.09.006
  3. Wong M.C.S., Fung F.D.H., Leung C. et al. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. Sci Rep 2018;8:1129. doi: 10.1038/s41598-018-19199-z
  4. Van Osch F.H., Jochems S.H., van Schooten F.J. et al. Quantified relations between exposure to tobacco smoking and bladder cancer risk: A meta-analysis of 89 observational studies. Int J Epidemiol 2016;45(3):857–70. doi: 10.1093/ije/dyw044
  5. Cumberbatch M.G.K., Jubber I., Black P.C. et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol 2018;74(6):784–95. doi: 10.1016/j.eururo.2018.09.001
  6. Purdue M.P., Hutchings S.J., Rushton L., Silverman D.T. The proportion of cancer attributable to occupational exposures. Ann Epidemiol 2015;25(3):188–92. doi: 10.1016/j.annepidem.2014.11.009
  7. State of oncological care in Russia in 2012. Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2013. 232 p. (In Russ.).
  8. State of oncological care in Russia in 2013. Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2014. 235 p. (In Russ.).
  9. State of oncological care in Russia in 2014. Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2015. 236 p. (In Russ.).
  10. State of oncological care in Russia in 2015. Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2016. 236 p. (In Russ.).
  11. State of oncological care in Russia in 2016. Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2017. 236 p. (In Russ.).
  12. Malignant tumors in Russia in 2017 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2018. 250 p. (In Russ.).
  13. Malignant tumors in Russia in 2018 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2019. 250 p. (In Russ.).
  14. Malignant tumors in Russia in 2019 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2020. 252 p. (In Russ.).
  15. Malignant tumors in Russia in 2020 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2021. 252 p. (In Russ.).
  16. Karyakin O.B. Bladder cancer: what’s new in 2020–2021. Onkourologiya = Cancer Urology 2021;17(4):115–23. (In Russ.). doi: 10.17650/1726-9776-2021-17-4-115-123
  17. State of oncological care in Russia in 2021. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2022. 239 p. (In Russ.).
  18. Belyakova L.I., Shevchenko A.N., Sagakyants A.B., Filatova E.V. Markers of bladder cancer: their role and prognostic significance (literature review). Onkourologiya = Cancer Urology 2021;17(2):145–56. (In Russ.). doi: 10.17650/1726-9776-2021-17-2-145-156.
  19. Zlotta A.R., Roumeguere T., Kuk C. et al. Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer. Eur Urol 2011;59(6):1026–31. doi: 10.1016/j.eururo.2011.03.027
  20. Dobruch J., Oszczudłowski M. Bladder cancer: current challenges and future directions. Medicina (Kaunas) 2021;57(8):749. doi: 10.3390/medicina57080749

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.